Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study

• Päätekijät: Ekaterina I. Alexeeva (Tekijä), Dariya D. Vankova (Tekijä), Tatyana M. Dvoryakovskaya (Tekijä), Ksenia B. Isaeva (Tekijä), Rina V. Denisova (Tekijä), Anna V. Mamutova (Tekijä), Aleksandra M. Chomakhidze (Tekijä), Tatyana V. Radygina (Tekijä), Irina V. Zubkova (Tekijä), Natalia E. Tkachenko (Tekijä), Anna N. Fetisova (Tekijä), Olga L. Lomakina (Tekijä), Yanina O. Orlova (Tekijä), Mariya K. Kurdup (Tekijä), Marina S. Gautier (Tekijä), Elizaveta A. Krekhova (Tekijä), Meyri S. Shingarova (Tekijä), Olga P. Galkina (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: "Paediatrician" Publishers LLC, 2020-08-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background. Immunological potency of 13-valent pneumococcal vaccine (PCV-13) in children with systemic juvenile idiopathic arthritis (SJIA) is still unstudied. Estimates of the genetically engineered biologic drugs (GEBD) effects on pneumococcal vaccination results also remain controversial.Objectiv...